A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of Inhaled GSK256066 in Mild to Moderate COPD Patients.
Latest Information Update: 15 Jul 2023
At a glance
- Drugs GSK 256066 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 18 May 2010 Results presented at 106th International Conference of the American Thoracic Society.
- 01 May 2009 Actual patient number (104) added as reported by ClinicalTrials.gov.
- 01 May 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.